Hemispherx Biopharma (HEB) Reports Q2 Loss of $0.04/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Hemispherx Biopharma (HEB) Reports Q2 Loss of $0.04/Share
August 13, 2015 9:00 AM EDT
PHILADELPHIA, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT: HEB) announced its financial results for the six months ended June 30, 2015. The net loss (including non-cash effects) was approximately $8,290,000 or $(0.04) per share as compared to a net loss of $8,792,000 or ($0.05) per share for the same six month period in 2014.
Cash, cash equivalents and marketable securities were approximately $15,714,000 at June 30, 2015 as compared to $16,108,000 as of December 31, 2014.
We have recently expanded our international collaborative programs with both major components of our treatment platform (Ampligen®, an experimental therapeutic, and Alferon® N, and FDA approved... More
August 13, 2015 8:30 AM EDT
PHILADELPHIA, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the "Company" or "Hemispherx") today announced that the Board has appointed Thomas Equels as the new President for Hemispherx Biopharma Inc. According to Peter Rodino, Chairman of the Audit Committee and an Independent Director, "On behalf of the Independent Directors, we are pleased to announce Equels' expanded role in providing a strong new executive emphasis creating greater operational efficiencies through seeking to achieve significant operational savings. He will also have a clear mandate from the Board to strengthen internal controls, achieve... More
August 13, 2015 8:30 AM EDT
PHILADELPHIA, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the "Company" or "Hemispherx") today announced that the Board has appointed Thomas Equels as the new President for Hemispherx Biopharma Inc. According to Peter Rodino, Chairman of the Audit Committee and an Independent Director, "On behalf of the Independent Directors, we are pleased to announce Equels' expanded role in providing a strong new executive emphasis creating greater operational efficiencies through seeking to achieve significant operational savings. He will also have a clear mandate from the Board to strengthen internal controls, achieve... More
